Latest News

19 July 2017

Appendix 4C - Quarterly Cashflow Report

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 June 2017.

Read more

4 July 2017

Shareholder Update July 2017

In this issue: 

>> Starpharma sells Agrochemicals business to Agrium for $35M cash

>> DEP®  irinotecan outperforms irinotecan in multiple cancer models

>> DEP®  docetaxel, DEP®  cabazitaxel and scale-up facilities

>> AstraZeneca pays US$2M DEP®  milestone to Starpharma

>> VivaGel®  BV phase 3 results timing and commercialisation

>> VivaGel®  condom launched in Canada

>> Sale of Ansell's Sexual Wellness division

>> Starpharma News & Events

Download: Shareholder Update July 2017 ( pdf file, 710kb)

4 July 2017

VivaGel® BV phase 3 results timing and commercialisation

Starpharma today announced revised timing for results of its two pivotal VivaGel® BV phase 3 trials for the prevention of recurrent bacterial vaginosis – now expected to be available in late July/early August 2017. 

Read more

14 June 2017

Sale of Agrochemicals Business Investor Presentation

Melbourne, Australia; 14 June 2017: Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), will be holding an investor conference call today at 11am (AEST) to discuss the sale of its Agrochemicals business to Agrium Inc., for $35 million. A presentation featuring further information on the transaction is available.

Read more

In the media

23 June 2017

Starpharma’s sale of its agrochemical business and technology, expands Agrium’s tech base

The sale of Starpharma’s agrochemical business was recently covered in Farm Weekly, highlighting the unique opportunity that Starpharma’s Priostar® dendrimer technology brings to the agrochemical market and the commercial value Agrium saw in the technology. In the article, Starpharma CEO Dr Jackie Fairley details the sale, including the patent transfer, total sale proceeds and the implications for the Company.

Go to article (external link)

20 June 2017

Starpharma featured on Business IQ, Sky Business News

Starpharma CEO Dr Jackie Fairley was interviewed on Sky Business News where she spoke to Business IQ host James Daggar-Nickson about dendrimer technologies and how the company develops products for a wide range of applications using the platform technology. Dr Fairley also discussed Australian innovation and the company's recent sale of its agrochemical business to global agricultural product giant Agrium.

Go to clip (external link)

14 June 2017

Finance News Network: Starpharma sells Agrochemicals business for $35M

Finance News Network noted Starpharma’s transaction to sell Starpharma Agrochemicals to Agrium Inc. for A$35M in cash consideration. The piece added that cash proceeds from the sale will allow Starpharma to focus on its core pharmaceutical development portfolio.

Go to the article (external link) 

14 June 2017

Starpharma’s sale of its agrochemical business to Agrium for A$35M noted in The Land

The sale of Starpharma’s agrochemical business was covered in The Land, with the article highlighting the innovation behind the Priostar® technology and how Agrium saw the acquisition as a strategic fit for their product portfolio. 

Go to article (external link)

Shareholder Updates

4 July 2017

Shareholder Update July 2017

In this issue: 

>> Starpharma sells Agrochemicals business to Agrium for $35M cash

>> DEP®  irinotecan outperforms irinotecan in multiple cancer models

>> DEP®  docetaxel, DEP®  cabazitaxel and scale-up facilities

>> AstraZeneca pays US$2M DEP®  milestone to Starpharma

>> VivaGel®  BV phase 3 results timing and commercialisation

>> VivaGel®  condom launched in Canada

>> Sale of Ansell's Sexual Wellness division

>> Starpharma News & Events

Download: Shareholder Update July 2017 ( pdf file, 710kb)

19 January 2017

Shareholder Update January 2017

In this issue:

›› Enrolment completed for phase 3 program: VivaGel® BV for prevention of recurrence

›› VivaGel® BV granted QIDP and Fast Track designation by US FDA

›› Favourable revision to FDA guidance for BV Treatment

›› VivaGel® condom approved in Canada; licensed in China and Iran

›› New DEP® partnered programs with AstraZeneca and world leading antibody-drug conjugate companies

›› DEP® docetaxel phase 1 program in final expansion phase; preparations underway for phase 2

›› DEP® cabazitaxel shows no neutropenia

›› DEP® irinotecan internal program shows superior performance

Download: Shareholder Update January 2017  (pdf file, 752kb)


Sign up to receive news here

© Starpharma Holdings Limited 2017